お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
962195

結膜炎治療薬の世界市場:将来展望 (2020~2027年)

Global Conjunctivitis Treatment Market - 2020-2027

出版日: 受注後作成 | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.58円
結膜炎治療薬の世界市場:将来展望 (2020~2027年)
出版日: 受注後作成
発行: DataM Intelligence
ページ情報: 英文
納期: 約2営業日
  • 全表示
  • 概要
  • 目次
概要

現在、発展途上国を中心に結膜炎の有病率が上昇中で、それが結膜炎治療薬の市場拡大の大きな要因となっています。また、衛生意識や関連知識の普及浸透や各国政府の積極的支援なども、市場の成長促進に貢献しています。他方、近い将来に「特許の崖」に直面し、安価なジェネリック医薬品や入手し易くなることが、市場成長の妨げとなる可能性もあります。

当レポートでは、世界の結膜炎向け治療薬の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、疾患の種類別・薬剤クラス別・エンドユーザー別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。

目次

第1章 世界の結膜炎治療薬市場:分析手法・範囲

第2章 世界の結膜炎治療薬市場:市場の定義と概要

第3章 世界の結膜炎治療薬市場:エグゼクティブサマリー

第4章 世界の結膜炎治療薬市場:市場力学

  • 市場への影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響力の分析

第5章 世界の結膜炎治療薬市場:産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • 価格分析
  • 製品分析
  • COVID-19の影響分析

第6章 世界の結膜炎治療薬市場:疾患の種類別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):疾患の種類別
  • 市場求心力指数:疾患の種類別
    • アレルギー性結膜炎
    • 細菌性結膜炎
    • ウイルス性結膜炎

第7章 世界の結膜炎治療薬市場:薬剤クラス別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):薬剤クラス別
  • 市場求心力指数:薬剤クラス別
    • 抗生物質
    • 眼科用ステロイド剤
    • 非ステロイド性抗炎症薬(NSAIDS)
    • 抗ヒスタミン薬
    • その他

第8章 世界の結膜炎治療薬市場:エンドユーザー別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):エンドユーザー別
  • 市場求心力指数:エンドユーザー別
    • 専門クリニック
    • その他

第9章 世界の結膜炎治療薬市場:地域別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):地域別
  • 市場求心力指数:地域別
  • 北米
    • イントロダクション
    • 域内市場の固有の動向
    • 市場規模の分析と対前年成長率 (YoY):疾患の種類別
    • 市場規模の分析と対前年成長率 (YoY):薬剤クラス別
    • 市場規模の分析と対前年成長率 (YoY):エンドユーザー別
    • 市場規模の分析と対前年成長率 (YoY):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第10章 世界の結膜炎治療薬市場:競合情勢

  • 競争シナリオ
  • 市場ポジショニング/シェア分析
  • 企業合併・買収 (M&A) の分析

第11章 世界の結膜炎治療薬市場:企業プロファイル

  • Boehringer Ingelheim GmbH
    • 企業概要
    • 製品のポートフォリオ/概略
    • 近年の動向
    • 財務分析:概要
  • Allergan Inc.
  • Sanofi-Aventis
  • Novartis AG
  • Bausch & Lomb Inc.
  • CIBA Vision Ophthalmics
  • Pfizer Inc.
  • Merck & Co., Inc.
  • 参天製薬
  • Akron Incorporated
  • その他の企業

第12章 世界の結膜炎治療薬市場:重要考察

第13章 DataM Intelligenceについて

目次

Market Overview

Conjunctivitis is a common condition that causes redness and inflammation of the thin layer of tissue that covers the front of the eye. It can be highly contagious. But it's rarely serious. It's very unlikely to damage the vision. Conjunctivitis caused by some bacteria and viruses can spread easily from person to person, but it isn't a serious health risk if diagnosed promptly. If it happens in a newborn baby, though, tell a doctor right away, as it might be an infection that threatens the baby's vision.

Allergies are also a common cause of conjunctivitis. The cells in the conjunctiva can react to an allergen. Some examples of allergens include grass, dust, animal fur, or mascara. Both viral and bacterial conjunctivitis can occur along with colds or symptoms of a respiratory infection, such as a sore throat. Other symptoms of conjunctivitis include itchiness and watering of the eyes, and sometimes a sticky coating on the eyelashes.

Conjunctivitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae requires aggressive antibiotic therapy, but conjunctivitis due to other bacteria is usually self-limited. Chronic conjunctivitis is usually associated with blepharitis, recurrent styes or meibomianitis. Treatment requires good eyelid hygiene and the application of topical antibiotics as determined by culture. Allergic conjunctivitis is distinguished by severe itching and allergen exposure.

Market Dynamics:

The market is driven is the increasing prevalence of conjunctivitis in developing countries is one of the factors driving the global market during the forecast period. Surge in the prevalence of sexually transmitted diseases (STDs) is another factor likely to propel the global market during the forecast period. Factors such as poor hygiene conditions, premature deliveries, and maternal sexually transmitted infection are some of the risk factors for neonatal conjunctivitis. Lack of awareness about the treatment of the disease in developing countries and lack of coverage of medicines in these countries are some of the factors restraining the global neonatal conjunctivitis treatment market during the forecast period..

The market is also driven by rise in air pollution in major cities across the globe. A research study published in 2016 by the National Center for Biotechnology Information (NCBI) revealed that ambient air pollution and weather changes are responsible for the occurrence as well as worsening of allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of conjunctiva with the outside environment. Hence, rise in air pollution propels the global conjunctivitis treatment market.

The National Institute of Health has stated in its 2017 report that the prevalence of conjunctivitis is around 6-30% in the general population and up to 30% in the children across the globe. As the disease is very common, treatment for the same is easily available. Most of the time, the disease is self-diagnosable and there is the least need of undergoing any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. As per the article published by a journal named Clinical Epidemiology and Global Health, it was found that during the year 2019, the prevalence of allergic conjunctivitis was around 12.22% and the number of men suffering from this disease is higher than that of females in India.

Rise in awareness among people about the disease and its treatment is also boosting the market. Several states are actively promoting treatment of the disease. Easy availability of the treatment is boosting the market. Rise in disposable income is also driving the growth of the market in the forecast period.

However, the market is expecting to face a patent cliff in the coming years. The availability of certain cost effective generic medicines is likely to hamper the market growth extensively. The scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of market. Dearth of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline is affecting the market growth in the forecast period.

Moreover, the outbreak of the COVID-19 pandemic across the globe is set to negatively impact the global market growth. Despite the patients suffering from conjunctivitis tend to be at a high risk of getting injected by viral conjunctiva that is usually caused because of adenovirus, the market is expected to undergo a decline. While coronavirus also causes several similar ocular signs and symptoms, such as conjunctivitis infection, watery discharge, photophobia, and eye irritation.

Due to the stringent lockdowns imposed by governments across the globe, the postponement or cancellations of non-life-threatening medical visits is expected to restrict the market growth as lesser prescriptions for conjunctivitis will be issued in this time period. This factor will hamper the market growth in the forecast period.

Segment Analysis

The global conjunctivitis treatment market is segmented based on disease type into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment held the largest market share. The allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. The people having allergies are more likely to develop allergic conjunctivitis.

As stated by the Asthma and Allergy Foundation of America, approximately 30% of the adults and 40% of the children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust. This factor will drive the growth of the market in the forecast period.

A research study published in 2017 by the National Institutes of Health (NIH) indicated that the number of patients being diagnosed with allergic conjunctivitis is increasing globally. This increase in incidence rate propels the global allergic conjunctivitis treatment market. Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors are driving the growth of the market in the forecast period.

The bacterial conjunctivitis segment is expected to have positive market growth in the forecast period. Bacterial conjunctivitis is one of the major eye problem encountered worldwide and are caused by bacteria's such as Moraxella and Chlamydia trachomatis. These bacteria's are responsible for causing persistent conjunctivitis with higher level of redness. Most of the cases of bacterial conjunctivitis are acute and self-limiting and not a major cause of serious health problem however, due to its high prevalence the infection can have large impact on the society as individuals tend to miss their school or work.

The increasing cases of bacterial conjunctivitis demand efficient medication, which supports the growth of bacterial conjunctivitis drugs market. Bacterial conjunctivitis spreads because of poor hygiene, immune compromise, and ocular diseases such as dry eye, blepharitis, and contaminated cosmetics. It can be prevented by maintaining proper hygiene and also hand wash reduces the chances of bacterial conjunctivitis. This factor will drive the growth of the market in the forecast period.

Further, the market is also classified based on drug class as antibiotics, ophthalmic steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antihistamines, others. The antibiotics segment is held the largest market share. Antibiotics may help shorten the length of infection, reduce complications, and reduce the spread to other. Antibiotics may be necessary in people whose immune system is compromised. In certain cases where an underlying infection elsewhere in the body may be causing conjunctivitis symptoms, you may be prescribed antibiotics to swallow in tablet form. Standard antibiotic treatments often will work for ordinary bacterial infections related to staphylococcus (staph) or streptococcus (strep) infections, which are the usual causes of bacterial conjunctivitis in adults. This factor will drive the growth of the market in the forecast period.

A typical antibiotic treatment often will work for these types of bacterial infections without the need to swab the eye and send off a sample (culture) for evaluation. If the initial treatment doesn't work, then a culture may be needed so that treatment can be changed to a more specialized type of antibiotic.

Geographical Presentation

By region, the conjunctivitis treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global conjunctivitis treatment market and is expected to grow at the highest CAGR during the forecast period due to presence of large number of key players operating in the conjunctivitis treatment market.

According to the National Institute of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer. Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the forecast period. According to the American Society of Cataract and Refractive Surgery (ASCRS), around 50 million to 60 million people in the U.S. had allergic conjunctivitis in 2015. This factors are expected to fuel the overall market growth across the region.

The Asia-Pacific region is expected to have third-largest share due to increase in the prevalence of infections, poor hygiene conditions in developing countries, and prolonged deliveries in some of the countries in the region. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia are expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region.

Competitive Analysis

The conjunctivitis treatment market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Novartis AG, Bausch & Lomb Inc., CIBA Vision Ophthalmics, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the conjunctivitis treatment market across the globe.

For instance, In June 2017, Nicox received an approval from the FDA for Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. The approval of Zerviate marks an important commercial milestone to bring first topical ocular formulation of cetirizine, a second generation antihistamine and improve the millions of people suffering from conjunctivitis.

In December 2018, Alembic Pharmaceuticals Limited received an abbreviated New Drug application approval from the FDA for olopatadine hydrochloride, selective H1-receptor antagonist for the treatment of allergic conjunctivitis. The approval of olopatadine hydrochloride strengthens the company's generic portfolio as well as improves the treatment paradigms for parent's suffering from allergic conjunctivitis.

Why Purchase the Report?

  • Visualize the composition of the global conjunctivitis treatment market products in terms of disease type, drug class and end-user and highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the global conjunctivitis treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global conjunctivitis treatment market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The global conjunctivitis treatment market report will provide access to approximately 59 market data tables, 55 figures, and 200 pages

Target Audience2022

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Table of Contents

1. Global Conjunctivitis Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Conjunctivitis Treatment Market - Market Definition and Overview

3. Global Conjunctivitis Treatment Market - Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by End users
  • 3.4. Market Snippet by Region

4. Global Conjunctivitis Treatment Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Number of People Suffering From Conjunctivitis
      • 4.1.1.2. Easy Availability of the Treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Alternative Treatments Such as Home Remedies
  • 4.2. Impact Analysis
  • 4.3. Opportunity

5. Global Conjunctivitis Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Product Analysis
  • 5.6. COVID-19 Impact Analysis

6. Global Conjunctivitis Treatment Market - By Disease Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.3. Market Attractiveness Index, By Disease Type
    • 6.3.1. Allergic Conjunctivitis *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 6.3.2. Bacterial Conjunctivitis
    • 6.3.3. Viral Conjunctivitis

7. Global Conjunctivitis Treatment Market - By Drug Class

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.3. Market Attractiveness Index, By Disease
    • 7.3.1. Antibiotics
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 7.3.2. Ophthalmic Steroids
    • 7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 7.3.4. Antihistamines
    • 7.3.5. Others

8. Global Conjunctivitis Treatment Market - By End-users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users Market Attractiveness Index, By End-users
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Introduction
      • 8.2.1.3. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
  • 8.3. Specialty Clinics
  • 8.4. Others

9. Global Conjunctivitis Treatment Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.5. . Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),End-users
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

10. Global Conjunctivitis Treatment Market Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Conjunctivitis Treatment Market Company Profiles

  • 11.1. Boehringer Ingelheim GmbH *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Developments
    • 11.1.4. Financial Overview
  • 11.2. Allergan Inc.
  • 11.3. Sanofi-Aventis
  • 11.4. Novartis AG
  • 11.5. Bausch & Lomb Inc.
  • 11.6. CIBA Vision Ophthalmics
  • 11.7. Pfizer Inc.
  • 11.8. Merck & Co., Inc.
  • 11.9. Santen Pharmaceuticals Co. Ltd.
  • 11.10. Akron Incorporated
  • List is not exhaustive

12. Global Conjunctivitis Treatment Market - Premium Insights

13. Global Conjunctivitis Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.